TerminatedNot Applicable

Endoscopic Injection of Mitomycin C for the Treatment of Pharyngoesophageal Stenosis

Stopped: adverse events was observed in all of them, with intense neck pain and ulcer evelopment

Brazil12 participantsStarted 2015-01-05

Plain-language summary

Management of pharyngoesophageal stenosis (PES) in patients after head and neck cancer (HNC) treatment remains a challenge. There are some cases of strictures refractory to dilation sessions. This study aimed to evaluate the efficacy of Mitomycin C (MMC) endoscopic injection for the treatment of refractory pharyngoesophageal stenosis. Patients and methods: This is a prospective study in patients with dysphagia following head and neck cancer treatment, without evidence suggestive of tumor recurrence, and refractory to endoscopic treatment. Theses undergo endoscopic dilation of the stenotic segment with thermoplastic bougies, followed by the injection of MMC.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with dysphagia following head and neck cancer treatment * Patients without endoscopic or radiological evidence suggestive of tumor recurrence * Patients refractory to endoscopic treatment Exclusion Criteria: * Endoscopic or radiological signs suggestive of tumor recurrence

What they're measuring

dysphagia

Timeframe: 2 years

Trial details

NCT IDNCT03540953

SponsorFauze Maluf Filho

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-05-05

View on ClinicalTrials.gov More Esophageal Stenosis trials